Thinking on decision velocity in pharma R&D.
Perspectives on decision governance, competitive pressure and the economics of indecision. Full articles available on request while our resource library is being finalized.
Why pharma R&D needs a decision layer, not another dashboard
Data platforms keep multiplying. Decisions keep lagging. The missing layer sits between signals and governance, above the systems of record, below the board.
The hidden cost of delayed R&D decisions
Every month of Phase III indecision carries a measurable direct cost, before internal FTEs, CMC, cost of capital and portfolio opportunity. Making that cost visible changes board behavior.
From Go/No-Go to Conditional Go: a new governance model
Binary decisions hide risk. Bounded, conditional, reviewable decisions expose it, and make continuation something a board can actually control.
Competitive pressure as a decision input in clinical development
A program can be scientifically sound and strategically destroyed. Competitor velocity, differentiation gap and market-window risk belong inside the decision, not in an appendix.
Decision velocity in the age of AI-enabled drug development
AI accelerates the production of signals. It does not accelerate cross-functional alignment. The advantage goes to organizations that convert intelligence into governed decisions fastest.
Want the full perspectives?
Request our white papers and briefing notes, or discuss how these ideas apply to your pipeline.